Back to Results
First PageMeta Content
Medicine / Clinical medicine / Cancer treatments / Immunology / Oncology / Immunotherapy / Virotherapy / Glioblastoma / Chemotherapy / Immune system / Cancer immunotherapy / ALECSAT


VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo
Add to Reading List

Document Date: 2016-07-12 04:22:18


Open Document

File Size: 362,33 KB

Share Result on Facebook
UPDATE